, and use of salbutamol during the 2 months of the trial showed that control of asthma was equally good, irrespective of the device used to deliver active beclomethasone.
SUMMARY 14 children with severe asthma were studied for 2 months in a double-blind cross-over trial to compare the efficacy of beclomethasone dipropionate delivered as an aerosol and as a powder from a rotahaler.* Inhalation via the aerosol was satisfactory in 13 patients, each of whom used the rotahaler correctly. Younger children preferred to use the rotahaler. Comparison of daily symptoms, twice daily peak expiratory flow rate (PEFR), and use of salbutamol during the 2 months of the trial showed that control of asthma was equally good, irrespective of the device used to deliver active beclomethasone.
There have been many studies demonstrating that beclomethasone dipropionate aerosol is safe and effective in the long-term management of severe childhood asthma (Morrow Brown and Storey, 1973;  Godfrey and K6nig, 1974; Lovera etal., 1976) . However, some children have difficulty using pressurised aerosols correctly, and consequently they have been denied the benefit of this form of treatment. Recently beclomethasone dipropionate has *Allen and Hanbury's .Research Division. become available in powder form mixed with a lactose base. It is dispensed in capsules which are used in a rotahaler* (Hallworth, 1977) . This device requires less co-ordination for effective use as the patient has only to breathe through it to inhale the powder. We have conducted a 2-month doubleblind randomised cross-over trial to determine whether beclomethasone dipropionate dispensed in this way is as effective in controlling symptoms of asthma as the usual preparation delivered as a metred dose from a pressurised aerosol. We also tried to find out if there were any problems associated with the use of the rotahaler in paediatric outpatient practice.
Patients and methods
Seven boys and 7 girls (mean age 9 7 years, range 4-8-15-1 years) were studied. They were all asthmatic and had previously been judged on clinical grounds to require treatment with beclomethasone. Before the trial they had been using beclomethasone regularly for a mean period of 1 year 10 months (range 0-5 years 5 months). 11 of them had failed to respond satisfactorily to treatment with sodium cromoglycate and one had failed to respond to treatment with regular theophylline. Two had previously been treated with alternate day oral prednisolone and had subsequently been weaned off this on to aerosol beclomethasone dipropionate. Three patients had required short courses of oral prednisolone during the previous year.
At the start of the trial all the patients were taught how to use both the aerosol and the rotahaler. At the end of the month each child was asked to demonstrate the use of both devices. He/she was given a score out of 10 for use of the aerosol. Droplet escape from nose or mouth, timing of aerosol release during inspiration, and size of breath taken (tidal or full vital capacity) were scored. It was noted whether the child was able to assemble the rotahaler correctly with the capsule in place, whether the powder fell on the floor, and whether he/she made an inspiratory effort great enough to inhale all the powder.
Throughout the trial the patients took two puffs of aerosol 4 times a day and powder from one capsule in the rotahaler 4 times a day. Each month one device contained active drug and the other an appropriate placebo. The order in which the patients received the drugs was randomly assigned by the hospital pharmacist and was not disclosed to the patients or the physicians until the trial was completed. All patients were given a salbutamol aerosol in addition to the beclomethasone to use as necessary for cough or wheeze. During the trial the patients recorded their symptoms each day in a diary card (Connolly and Godfrey, 1970) . They also recorded peak expiratory flow rate (PEFR) every morning and evening. This was measured as the best of 3 attempts using a calibrated peak flow gauge (Airmed Ltd). SUMMARY Cefuroxime (25 mg/kg) given intravenously every four hours to 7 children with bacterial meningitis resulted in satisfactory therapeutic blood and CSF levels. All children made a full recovery and side effects were absent.
Bacterial meningitis in children carries a 10-15% mortality rate and there can be significant neurological damage in children who recover (Goldacre, 1977) . The success of any antibiotic in the treatment of this disease depends on its antibacterial properties and the concentration that remains in the blood and CSF after systemic administration. Unfortunately, during the last few years, sulphonamide-resistant meningcocci have emerged (Lambert, 1974) , Haemophilus influenzae is now sometimes resistant to ampicillin because of r-lactamase production, and meningitis due to chloramphanicol-resistant H. influenzae has recently been reported (Kinmonth et al., 1978) . Therefore, triple treatment with a sulphonamide, ampicillin, and chloramphenicol is often used before the causative organism is known. Cefuroxime, unlike the other three agents, is highly active against all the organisms that commonly cause meningitis-namely Neisseria meningitidis, H. influenzae, and Streptococcus pneumoniae (O'Callaghan et al., 1976) . It was felt appropriate, therefore, to determine blood and CSF levels of cefuroxime in children with meningitis before this antibiotic was considered as an alternative treatment.
Patients, methods, and results
The treatment currently used at this hospital for children with meningitis consists of ampicillin (25 mg/kg), chloramphenicol (15 mg/kg), and sulphadimidine (25 mg/kg), by IV infusion every four hours for a period of up to 5 days. Treatment is modified depending on the sensitivity of the organism to these agents, and then it is continued orally for an additional period of 5 days.
Cefuroxime (25 mg/kg) was given intravenously by a 20-minute infusion every four hours to 7 children (6 boys; age range, 1 J-6 years) for periods of between one and 5 days in addition to the above treatment. The organism responsible for the meningitis in 3 children was N. meningitidis (all resistant to sulphadimidine), and in the other 4 it was H. influenzae. Sensitivity testing showed that all the isolated organisms were highly sensitive to cefuroxime. Blood samples were taken twice during treatment and plasma levels of cefuroxime were determined between 30 and 90 min and 4 hours after injection. CSF levels of cefuroxime were measured in 3 patients in whom lumbar punctures were clinically indicated; one child with CSF pressure had lumbar punctures performed 2 hours after a cefuroxime injection on 4 consecutive days. All samples were analysed by a high-pressure liquid chromatography method which enabled cefuroxime to be determined in the presence of other drugs.
Plasma levels of cefuroxime ( Figure) 
